TSHAHealthcare · BiotechnologyThe 12 Wall Street analysts covering Taysha Gene Therapies, Inc. hold a median 12-month price target of $13 — +105.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Taysha Gene Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Volatility (17): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TSHA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +105.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $11 → $13 |
| 2 July 2026 | Citizens | Reiterates | Market Outperform | — |
| 2 July 2026 | Citizens | Reiterates | Market Outperform | $11 |
| 30 June 2026 | Baird | Maintains | Outperform | — |
| 30 June 2026 | Baird | Maintains | Outperform | $12 → $15 |
| 30 June 2026 | Needham | Maintains | Buy | — |
| 30 June 2026 | Needham | Maintains | Buy | $12 |
| 23 June 2026 | B of A Securities | Maintains | Buy | — |
| 23 June 2026 | BMO Capital | Maintains | Outperform | — |
| 23 June 2026 | Citizens | Maintains | Market Outperform | — |
| 22 June 2026 | Needham | Maintains | Buy | — |
| 6 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Mar 2026 | Needham | Maintains | Buy | — |
| 3 Mar 2026 | Needham | Reiterates | Buy | — |
| 6 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 5 Jan 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 5 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 21 Oct 2025 | Raymond James | Initiates | Strong Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TSHA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 2% of US stocks
Cheaper than 13% of US stocks
Cheaper than 84% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Taysha Gene Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Taysha Gene Therapies, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the call. The item provides the conference call discussion for that reporting period.
Why it matters — A TSHA watcher would review the transcript for management's commentary on the company's latest quarterly results and outlook.
Taysha Gene Therapies reported during its Q2 earnings call that it has completed dosing in the REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome. The company is also preparing for a potential biologics license application submission.
Why it matters — Completion of dosing in both trials brings TSHA-102 closer to a regulatory submission, a key milestone for Taysha's lead pipeline candidate.
Taysha Gene Therapies reported its second quarter 2026 financial results and provided a corporate update. The company completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome, and expects to report topline data from a 6-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.
Why it matters — The completed dosing and upcoming topline data and FDA feedback on the BLA pathway mark key upcoming milestones for TSHA-102, the company's lead program for Rett syndrome.
On August 3, 2026, the Compensation Committee of Taysha Gene Therapies' Board granted a new employee restricted stock units representing 144,000 shares of common stock and an option to purchase 92,400 shares, under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The award was made as an inducement material to the individual's employment with the company.
Why it matters — This announcement is notable for TSHA watchers because it signals a new hire joining the clinical-stage gene therapy company, with the equity grant reflecting standard Nasdaq-listed inducement practices.
Taysha Gene Therapies announced it will report financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.
Why it matters — The scheduled date gives Taysha watchers a known time to hear the company's latest quarterly financial results and corporate updates.
The 12 Wall Street analysts covering Taysha Gene Therapies, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Taysha Gene Therapies, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Taysha Gene Therapies, Inc. 46 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Taysha Gene Therapies, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +105.3% from the last close, and Ticker Nerd's factor model ranks Taysha Gene Therapies, Inc. 46 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Taysha Gene Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TSHA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $19 over the next 12 months.
Taysha Gene Therapies, Inc. returned +112.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript". Taysha Gene Therapies, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the call. The item provides the conference call discussion for that reporting period.
Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.
CEO Mr. Sean P. Nolan · 99 employees · United States · https://www.tayshagtx.com